• Feryal H Rada


Objective: The aim of this study is to analyze the association of serum lipids and lipoproteins in patients with angina pectoris.
Methods: A total of 110 patients (60 males and 50 females) with angina pectoris aged (55±5) years and 80 healthy controls (43 males and
37 females) aged (45±4) years were enrolled in this case-control study from the clinic of Al Yarmouk Hospital. Serum lipids, lipoprotein(a) [Lp(a)],
apolipoprotein-A1, and apolipoprotein-B levels were measured and studied.
Results: The results of this study showed that increased odds of angina pectoris were associated with increased serum levels of Lp(a) more than
serum levels of apolipoprotein-B.
Conclusions: Analysis of Lp(a) may be an important determinant of cardiovascular disease diagnosis.
Keywords: Lipoprotein(a), Apolipoprotein-A1, Apo lipoprotein-B, Angina pectoris.


1. Malaguarnera M, Vacante M, Avitabile T, Malaguarnera M, Cammalleri L, Motta M. L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr 2009;89(1):71-6.
2. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302(18):1993-2000.
3. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: Risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255(2):188-205.
4. Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 2005;26:210-2.
5. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82(12A):57U-66.
6. Hervio L, Chapman MJ, Thillet J, Loyau S, Anglés-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 1993;82:392-7.
7. Berglund L, Ramakrishnan R. Lipoprotein(a): An elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004;24(12):2219-26.
8. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: Mechanistic insights from animal models. Clin Biochem 2004;37(5):333-43.
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18(6):499-502.
10. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-9.
11. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: A critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002;48(2):236-54.
12. Arsenault BJ, Rana JS, Stroes ES, Després JP, Shah PK, Kastelein JJ, et al. Beyond low-density lipoprotein cholesterol: Respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009;55:35-41.
13. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
14. Sniderman AD, Williams K, Contois JH, Monroe HM, Mc Queen MJ, de Graaf J. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;337:4-45.
15. Lavie CJ, Milani RV, O’Keefe JH. To B or not to B: Is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B? Mayo Clin Proc 2010;85:446-50.
16. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
17. Batalla A, Reguero JR, Cubero GI. Plasma lipoprotein(a) and severity of angiographic coronary artery disease. J Am Coll Cardiol 1999;33:590-1.
18. Miyata M, Biro S, Arima S, Hamasaki S, Kaieda H, Nakao S, et al. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J 1996;132:269-73.
19. Skinner JS, Farrer M, Albers CJ, Piper K, Neil HA, Adams PC. Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery. Heart 1997;78:131-5.
20. HPS-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17):1279-91.
21. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363(25):2406-15.
22. Mmr MM, Tripathy M, Majeed A. The prospect, promises and hindrances of statin base molecules: Look back to look forward. Int J Pharm Pharm Sci 2016;8:22-33.
23. Gururaja GM, Mundkinajeddu D, Kumar AS, Allanj J, Dethe SM, Agarwal A. Cholesterol lowering potentials of a blend of standardized methanol extracts of Moringa oleifera leaves and fruits in albino wistar rats. Int J Pharm Pharm Sci 2016;8:262-8.
287 Views | 301 Downloads
How to Cite
Rada, F. H. “ASSOCIATION OF LIPID FRACTIONS LEVELS WITH CARDIOVASCULAR DISEASE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 3, Mar. 2017, pp. 180-2, doi:10.22159/ajpcr.2017.v10i3.15984.
Original Article(s)